C4 Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
C4 Therapeutics, Inc. (CCCC) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $3.80 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-11
- C4 Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.88, a 40.69% decline year-over-year.
- C4 Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $3.17, a 56.63% decline year-over-year.
- C4 Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $7.31, a 26.91% increase year-over-year.
- C4 Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $5.76.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month |
|---|---|---|---|
| 2026-06-30 | $3.80 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | $1.88 10-Q · filed 2026-05-12 | ||
| 2025-09-30 | $2.92 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $2.92 10-Q · filed 2025-08-07 | ||
| 2025-03-31 | $3.17 10-Q · filed 2025-05-07 | ||
| 2024-09-30 | $6.86 10-Q · filed 2024-10-31 | ||
| 2024-06-30 | $6.95 10-Q · filed 2024-08-01 | ||
| 2024-03-31 | $7.31 10-Q · filed 2024-05-08 | ||
| 2023-09-30 | $3.89 10-Q · filed 2023-11-01 | ||
| 2023-06-30 | $5.51 10-Q · filed 2023-08-08 | ||
| 2023-03-31 | $5.76 10-Q · filed 2023-05-04 | ||
| 2021-09-30 | $41.85 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | $42.25 10-Q · filed 2021-08-11 | ||
| 2021-03-31 | $44.48 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |